Noncoding RNAs: an emerging modulator of drug resistance in pancreatic cancer
Authors:
Open Access
- 25 July 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1226639
Abstract
Pancreatic cancer is the eighth leading cause of cancer-related deaths worldwide. Chemotherapy including gemcitabine, 5-fluorouracil, adriamycin and cisplatin, immunotherapy with immune checkpoint inhibitors and targeted therapy have been demonstrated to significantly improve prognosis of pancreatic cancer patients with advanced diseases. However, most patients developed drug resistance to these therapeutic agents, which leading to shortened patient survival. The detailed molecular mechanisms contributing to pancreatic cancer drug resistance remain largely unclear. The growing evidences have shown that noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), are involved in pancreatic cancer pathogenesis and development of drug resistance. In the present review, we systematically summarized the new insight on of various miRNAs, lncRNAs and circRNAs on drug resistance of pancreatic cancer. These results demonstrated that targeting the tumor-specific ncRNA may provide novel options for pancreatic cancer treatments.Keywords
This publication has 202 references indexed in Scilit:
- miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2Oncology Reports, 2013
- Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET OncoproteinPLOS ONE, 2013
- Epigenetic Regulation by Long Noncoding RNAsScience, 2012
- miR-17-5p Inhibitor Enhances Chemosensitivity to Gemcitabine Via Upregulating Bim Expression in Pancreatic Cancer CellsDigestive Diseases and Sciences, 2012
- The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progressionBritish Journal of Cancer, 2012
- Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cellsBiochemical and Biophysical Research Communications, 2011
- MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic CancerAnnals of Surgical Oncology, 2011
- Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic CancerPLOS ONE, 2010
- Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic AdenocarcinomaPancreas, 2009
- MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating CellsPLOS ONE, 2009